GENEVA (Reuters) – The World Health Organization’s chief scientist Soumya Swaminathan said on Monday she expected to hear more “this week or next week” about clinical trials of an Eli Lilly and Co COVID-19 antibody treatment that were paused because of a safety concern.
U.S. drug maker Lilly said earlier this month it was pausing the government-sponsored trial, called ACTIV-3, which was testing the treatment on COVID-19 patients who required hospitalization.
(Reporting by Michael Shields and Stephanie Nebehay; Editing by Alex Richardson)
